<DOC>
	<DOCNO>NCT00843804</DOCNO>
	<brief_summary>The Oncoped 2006 study implement multicenter prospective surveillance module nosocomial infection pediatric cancer patient .</brief_summary>
	<brief_title>Surveillance Nosocomial Infections Pediatric Cancer Patients</brief_title>
	<detailed_description>Type study : Prospective multicenter surveillance study refer file data collect routinely management infectious thrombotic complication high risk pediatric cancer patient . Primary aim Oncoped 2006 Study 1 . To describe epidemiology select nosocomial infection pediatric cancer patient well unit level reference database cumulative data prospective multicenter surveillance perspective . 2 . To allow participate institution - compare result center reference database ( median 75. percentile ) . - reduce incidence density nosocomial infection incidence rate catheter-associated infection pediatric cancer patient . 3 . To promote patient 's safety mean quality assurance reduction nosocomial infection . 4 . To describe objective outcome variable relate documented NI event ( mortality , duration hospitalization , need intensive care , need surgical intervention ) 5 . To intensify practical collaboration health care team infection control personnel infectious disease specialist clinical context . 6 . To describe distribution bacterial pathogen blood stream infection determine sensitivity ( minimal inhibitory concentration ) bacterial pathogen detect blood culture first second line antimicrobial agent high risk population standardize method ( central reference laboratory ) . 7 . To detect bacterial isolates emerge type antimicrobial resistance . 8 . To describe therapeutic use antibacterial antifungal agent pediatric cancer patient related nosocomial infection . 9 . To describe incidence incidence density invasive Aspergillosis pediatric cancer patient . 10 . To describe clinical impact common emerge viral respiratory pathogen ( RSV , Influenza , hMPV , hCoV , hBoV ) pediatric cancer patient nosocomial low respiratory tract infection ( central reference laboratory emerge viral pathogen ) . 11 . What incidence incidence rate ( per 1000 catheter utilization day ) thrombotic event pediatric cancer patient patient hemophilia , CVAD use ? 12 . How many child event congenital risk factor ( thrombophilia ) ? 13 . What objective outcome parameter population consider antithrombotic treatment ( discretion attend physician ) ?</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<criteria>pediatric cancer patient receive inpatient treatment chemotherapy , radiotherapy stem cell transplantation inform consent inpatient treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>nosocomial infection</keyword>
	<keyword>bloodstream infection</keyword>
	<keyword>central venous catheter</keyword>
	<keyword>invasive Aspergillosis</keyword>
	<keyword>Clostridium difficile associate disease</keyword>
</DOC>